Halozyme Therapeutics Inc.
HALO
Market Cap$4.89B
Close$
$16.50
58% downside
Current Fair Value
58% downsideOvervalued by 58% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.89 Billion |
|---|---|
| Enterprise Value | $6.05 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $2.1 |
| Beta | 0.0 |
| Outstanding Shares | 127,054,240 |
| Avg 30 Day Volume | 873,425 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 17.35 |
|---|---|
| PEG | 36.17 |
| Price to Sales | 6.55 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.3 |
| Enterprise Value to EBIT | 17.92 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 17.89 |
Revenue Sources
No data
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley